Xeris Biopharma HoldingsXERS -3.30%71 Quick Ratio is 1.50 as of Mar. 2026, which is 38% below its 10-year median of 2.42. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 999 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 51.65% on this metric.
Xeris Biopharma Holdings has a quick ratio of 1.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Xeris Biopharma Holdings's Quick Ratio or its related term are showing as below:
XERS'
s Quick Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.42 Max: 16.53
Current: 1.5
During the past 10 years, Xeris Biopharma Holdings's highest Quick Ratio was 16.53. The lowest was 1.17. And the median was 2.42.
XERS's Quick Ratio is ranked better than 51.65% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs XERS: 1.50
Xeris Biopharma Holdings (NAS:XERS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Xeris Biopharma Holdings Quick Ratio Related Terms
Xeris Biopharma Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Xeris Biopharma Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (XERS) has a Quick Ratio of 1.50 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Xeris Biopharma Holdings and its competitors. This is 38% below median its historical median of 2.42. Over the past decade, Xeris Biopharma Holdings' Quick Ratio has ranged from 1.17 to 16.53. According to the industry distribution chart, Xeris Biopharma Holdings ranks #483 out of 999 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is Xeris Biopharma Holdings' Quick Ratio too high?
Xeris Biopharma Holdings' current Quick Ratio of 1.50 is 38% below median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 16.53. The Drug Manufacturers industry median Quick Ratio is 1.45. Xeris Biopharma Holdings' value of 1.50 is 3.4% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #483 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Quick Ratio compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #483 out of 999 companies for Quick Ratio. This puts Xeris Biopharma Holdings in the upper half of its industry. The industry median Quick Ratio is 1.45. Xeris Biopharma Holdings' value of 1.50 is 3.4% above this benchmark. Historically, Xeris Biopharma Holdings' own Quick Ratio has ranged from 1.17 to 16.53 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 1.45, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Quick Ratio of 1.50 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Quick Ratio is 1.50, which is 38% below median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Quick Ratio is 1.50, which is 38% below median its 10-year median of 2.42 and 3.4% above the Drug Manufacturers industry median of 1.45. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Quick Ratio is 1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Quick Ratio: 1.50 (38% below median its 10-year median of 2.42)
GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
Industry Position: 3.4% above the Drug Manufacturers median (#483 of 999)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
